LF
ALXN

Lee Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Lee Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11
Closed -$2K – 756
2021
Q2 		$2K Buy
+11
New +$1.89K ﹤0.01% 646
2018
Q3 		– Sell
-23
Closed -$3K – 774
2018
Q2 		$3K Sell
23
-3
-12% -$351 ﹤0.01% 709
2018
Q1 		$3K Buy
+26
New +$3.11K ﹤0.01% 689

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Lee Financial's ALXN Position: Q3 2021 in Review

Lee Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11 shares — an estimated $2K sold.

Lee Financial first reported a position in ALXN in Q1 2018 and held it in 3 quarters. The position peaked at $3K in Q2 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Lee Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Lee Financial sold 11 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2K.
  • Lee Financial first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Lee Financial's Alexion Pharmaceuticals position peaked at $3K in Q2 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Lee Financial's 13F filing for Q3 2021, filed 12 Nov 2021.